Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Billions Lost In Productivity Due To Vision Impairment
Corrected vision impairment could prevent billions of dollars in lost productivity annually, according to a study by researchers from the Johns Hopkins Bloomberg School of School of Public Health, the International Centre for Eyecare Education, the University of New South Wales and the African Vision Research Institute. Researchers estimate that nearly 158 million people globally suffer with vision impairment resulting from uncorrected refractive error, which can usually be eliminated with a pair of eyeglasses and an eye examination. This is the first study to estimate the productivity loss from uncorrected refractive error and is published in the June 2009 issue of the Bulletin of the World Health Organization.
generic viagra online
The First Harmonised Standard For Organic Health And Beauty, UK
The Soil Association is pleased to announce a new EU-wide, harmonised standard for organic health and beauty products.
News of the day
Support For Reform Softens, Pollster Reflects On How Public Mood Is Shaped
A new survey suggests that "most Americans support an overhaul of the health system, but the percentage who believe they (and their family) will be worse off from the change" has gone from 11 percent to 21 percent in the past five months, Kaiser Health News reports. "The survey, conducted July 7 to July 14 by the Kaiser Family Foundation, found 56 percent of Americans say now is the time for the country to overhaul the health system. That"s down from 61 percent in June." (note: KHN is a program of Kaiser Family Foundation).
Public Health

BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)

The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration. Biferonex was expected to be used to treat patients with relapsing-remitting multiple sclerosis characterised by two or more exacerbations of neurological symptoms in the previous two years. The application for the marketing authorisation for Biferonex was submitted to the Agency on 24 July 2007. On 19 February 2009, the Agency"s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation. Following this, the company requested a re-examination of the opinion, which was under review by the CHMP at the time of the withdrawal. The company stated in its official letter that its decision to withdraw the application was based on the fact that the additional information provided in support of the re÷¬examination had not changed the Committee"s view on the benefit-risk balance of Biferonex. More information about Biferonex and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 22-25 June 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. This press release, together with other information on the work of the Agency, can be found on the Agency"s website: http://www.emea.europa.eu EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009